Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 199

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Open access
Borghaei, Hossein, Langer, Corey J., Gadgeel, Shirish, Papadimitrakopoulou, Vassiliki A., Patnaik, Amita, Powell, Steven F., Gentzler, Ryan D., Martins, Renato G., Stevenson, James P., Jalal, Shadia I., Panwalkar, Amit, Yang, James Chih-Hsin, Gubens, Matthew, Sequist, Lecia V., Awad, Mark M., Fiore, Joseph, Saraf, Sanatan, Keller, Steven M., Gandhi, Leena · 2019 · Journal of Thoracic Oncology

Abstract

Introduction: Cohort G of KEYNOTE‐021 (NCT02039674) evaluated the efficacy and safety of pembrolizumab plus pemetrexed‐carboplatin (PC) versus PC alone as first‐line therapy for advanced nonsquamous NSCLC. At the primary analysis (median follow‐up time 10.6 months), pembrolizumab significantly improved objective response rate (ORR) and progression‐free survival (PFS); the hazard ratio (HR) for overall survival (OS) was 0.90 (95% confidence interval [CI]: 0.42‐1.91). Herein, we present an updated analysis. Methods: A total of 123 patients with previously untreated stage IIIB/IV nonsquamous NSCLC without EGFR and/or ALK receptor tyrosine kinase gene (ALK) aberrations were randomized 1:1 to four cycles of PC with or without pembrolizumab, 200 mg every 3 weeks. Pembrolizumab treatment continued for 2 years; maintenance pemetrexed was permitted in both groups. Eligible patients in the PC‐alone group with radiologic progression could cross over to pembrolizumab monotherapy. p Values are nominal (one‐sided p < 0.025). Results: As of December 1, 2017, the median follow‐up time was 23.9 months. The ORR was 56.7% with pembrolizumab plus PC versus 30.2% with PC alone (estimated difference 26.4% [95% CI: 8.9%‐42.4%, p = 0.0016]). PFS was significantly improved with pembrolizumab plus PC versus PC alone (HR = 0.53, 95% CI: 0.33‐0.86, p = 0.0049). A total of 41 patients in the PC‐alone group received subsequent anti‐programmed death 1/anti‐programmed death ligand 1 therapy. The HR for OS was 0.56 (95% CI: 0.32‐0.95, p = 0.0151). Forty‐one percent of patients in the pembrolizumab plus PC group and 27% in the PC‐alone group had grade 3 to 5 treatment‐related adverse events. Conclusions: The significant improvements in PFS and ORR with pembrolizumab plus PC versus PC alone observed in the primary analysis were maintained, and the HR for OS with a 24‐month median follow‐up was 0.56, favoring pembrolizumab plus PC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.08.004

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 199

Metadata

Authors
Borghaei, H., Langer, C. J., Gadgeel, S., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., Panwalkar, A., Yang, J. C.-H., Gubens, M., Sequist, L. V., Awad, M. M., Fiore, J., Saraf, S., Keller, S. M., & Gandhi, L.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2019-01
Volume
14
Issue
1
Pages
124-129
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2888059202
Cited by
199
References
3
FWCI
23.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1016/j.jtho.2018.08.004
The paper
Borghaei, H., Langer, C. J., Gadgeel, S., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., Panwalkar, A., Yang, J. C.-H., Gubens, M., Sequist, L. V., Awad, M. M., Fiore, J., Saraf, S., Keller, S. M., & Gandhi, L. (2019). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.08.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.